ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP

Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against ImmunityBio, Inc. (ImmunityBio) (NASDAQ: IBRX) on behalf of those who purchased or acquired ImmunityBio securities between January 19, 2026, and March 24, 2026, inclusive. The lawsuit is filed in the United States District Court for the Central District of California and is captioned Douglas v. ImmunityBio, Inc., Case No. 2:26-cv-03261 (C.D. Cal.). Investors have until May 26, 2026, to file for lead plaintiff status.

CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:

If you purchased or acquired ImmunityBio securities and have lost money on your investment, you are encouraged to contact KTMC attorney Jonathan Naji, Esq. at:

• [phone]
• [e-mail]
• https://www.ktmc.com/ibrx-immunitybio-inc-class-action-lawsuit?utm_sou ...

There is no cost or obligation to speak with an attorney.

Learn more about ImmunityBio, Inc. on YouTube:

• ImmunityBio, Inc. Securities Class Action Lawsuit (long video)
• ImmunityBio, Inc. Securities Class Action Lawsuit (short video)

IMMUNITYBIO, INC. CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY:

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company’s business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) ImmunityBio’s claim that Anktiva is a cancer vaccine was false; (2) ImmunityBio’s Executive Chairman and Global Scientific and Medical Officer materially overstated Anktiva’s capabilities; and (3) as a result of the foregoing, Defendants’ positive statements about the company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Why did ImmunityBio’s Stock Drop?

On March 24, 2026, Bloomberg reported that ImmunityBio had receive a Warning Letter from the FDA stating that the company’s Executive Chairman and Global Chief Scientific and Medical Officer, Patrick Soon-Shiong, made inaccurate claims on a podcast regarding ImmunityBio’s lead biologic product, Anktiva, including that the drug “can cure and even prevent all cancer.” The FDA thus “determined that the TV ad and podcast [for Anktiva] are false or misleading” and “make the distribution of the drug in violation of the Federal Food, Drug, and Cosmetic Act.”

Schreibe Deinen Kommentar